← Back to Search

Transoral Robotic Surgery + Neck Dissection for Squamous Cell Carcinoma (ORATOR Trial)

Phase 2
Waitlist Available
Led By Anthony Nichols, MD
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at the end of 3 years and at the end of 5 years
Awards & highlights

ORATOR Trial Summary

This trial will compare the two treatments to see which is more effective in treating early-stage squamous cell carcinoma of the oropharynx.

Eligible Conditions
  • Squamous Cell Carcinoma

ORATOR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at the end of 3 years and at the end of 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and at the end of 3 years and at the end of 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Quality of Life
Secondary outcome measures
Overall Survival
Progression-free survival
Quality of life at other time points
+2 more

ORATOR Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Transoral Robotic Surgery + Neck DissectionExperimental Treatment1 Intervention
Transoral robotic excision will be carried out using the da Vinci surgical robot. The spatula cautery will be used to remove the tumours with 1 cm margins. At the time of surgery circumferential margins will be taken and sent for frozen section analysis. The resection will proceed until negative margins are obtained if feasible.
Group II: Radiotherapy plus or minus ChemotherapyActive Control1 Intervention
Radiotherapy plus or minus chemotherapy with surgical treatment for salvage of persistent disease

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
656 Previous Clinical Trials
413,360 Total Patients Enrolled
Anthony Nichols, MDPrincipal InvestigatorLondon Regional Cancer Program of the Lawson Health Research Institute
David Palma, MD, PhDPrincipal InvestigatorLondon Regional Cancer Program of the Lawson Health Research Institute
3 Previous Clinical Trials
168 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~5 spots leftby Apr 2025